MX2022011583A - Dpp3 en pacientes infectados con coronavirus. - Google Patents

Dpp3 en pacientes infectados con coronavirus.

Info

Publication number
MX2022011583A
MX2022011583A MX2022011583A MX2022011583A MX2022011583A MX 2022011583 A MX2022011583 A MX 2022011583A MX 2022011583 A MX2022011583 A MX 2022011583A MX 2022011583 A MX2022011583 A MX 2022011583A MX 2022011583 A MX2022011583 A MX 2022011583A
Authority
MX
Mexico
Prior art keywords
dpp3
level
therapy
correlating
determined
Prior art date
Application number
MX2022011583A
Other languages
English (en)
Inventor
Andreas Bergmann
Original Assignee
4TEEN4 Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20179763.6A external-priority patent/EP3922993A1/en
Application filed by 4TEEN4 Pharmaceuticals GmbH filed Critical 4TEEN4 Pharmaceuticals GmbH
Publication of MX2022011583A publication Critical patent/MX2022011583A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La materia objeto de la presente invención es un método para (a) diagnosticar o predecir el riesgo de deterioro potencialmente mortal o un evento adverso o (b) diagnosticar o pronosticar la gravedad de o (c) predecir o monitorear el éxito de una terapia o intervención o (d) guía de la terapia o estratificación de la terapia o (e) manejo del paciente en un paciente infectado con un coronavirus, el método comprende: determinar el nivel de dipeptidil peptidasa 3 (DPP3) en una muestra de fluido corporal del paciente, comparar el nivel de DPP3 determinada a un umbral predeterminado, y correlacionar el nivel de DPP3 determinada con el riesgo de deterioro potencialmente mortal o un evento adverso, o correlacionar el nivel de DPP3 determinada con la gravedad, o correlacionar el nivel de DPP3 determinada con el éxito de una terapia, o correlacionar el nivel de DPP3 con una cierta terapia o intervención, o correlacionar el nivel de DPP3 con el manejo del paciente. La materia objeto de la presente invención es un inhibidor de la actividad de DPP3 para usarse en la terapia o intervención en un paciente infectado con un coronavirus.
MX2022011583A 2020-03-16 2021-03-15 Dpp3 en pacientes infectados con coronavirus. MX2022011583A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062990166P 2020-03-16 2020-03-16
EP20163419 2020-03-16
US202063015205P 2020-04-24 2020-04-24
EP20179763.6A EP3922993A1 (en) 2020-06-12 2020-06-12 Dpp3 in patients infected with coronavirus
PCT/EP2021/056579 WO2021185786A1 (en) 2020-03-16 2021-03-15 Dpp3 in patients infected with coronavirus

Publications (1)

Publication Number Publication Date
MX2022011583A true MX2022011583A (es) 2022-10-18

Family

ID=74870834

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011583A MX2022011583A (es) 2020-03-16 2021-03-15 Dpp3 en pacientes infectados con coronavirus.

Country Status (9)

Country Link
US (1) US20230213519A1 (es)
EP (1) EP4121763A1 (es)
JP (1) JP2023518731A (es)
CN (1) CN115769076A (es)
AU (1) AU2021237689A1 (es)
BR (1) BR112022017277A2 (es)
CA (1) CA3171332A1 (es)
MX (1) MX2022011583A (es)
WO (1) WO2021185786A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024126793A1 (en) 2022-12-15 2024-06-20 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JPS6188884A (ja) 1984-10-04 1986-05-07 Sankyo Co Ltd エンケフアリナ−ゼｂ阻害物質およびその製法
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ATE490969T1 (de) 2001-08-30 2010-12-15 Biorexis Pharmaceutical Corp Modifizierte transferrin-fusionsproteine
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2006032436A2 (en) 2004-09-21 2006-03-30 Nascacell Technologies Ag. Use of microproteins as tryptase inhibitors
WO2009077175A1 (en) 2007-12-19 2009-06-25 Affibody Ab Polypeptide derived from protein a and able to bind pdgf
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
WO2011023685A1 (en) 2009-08-27 2011-03-03 Covagen Ag Il-17 binding compounds and medical uses thereof
JP5749733B2 (ja) 2009-12-14 2015-07-15 シル プロテインズ ゲーエムベーハーＳｃｉｌ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ フィブロネクチンのエキストラドメインｂに対する特異的結合活性を有する修飾ユビキチンタンパク質
SI2580236T1 (sl) 2010-06-08 2019-08-30 Pieris Pharmaceuticals Gmbh Muteini lipokalina solz, ki vežejo IL-4 R alfa
CA2898596A1 (en) 2013-01-28 2014-07-31 Gabriel GOJON ROMANILLOS Compositions for the systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
MX2018012856A (es) 2016-04-21 2019-07-10 Sphingotec Therapeutics Gmbh Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
EP3700937A2 (en) 2017-10-25 2020-09-02 4TEEN4 Pharmaceuticals GmbH Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress

Also Published As

Publication number Publication date
JP2023518731A (ja) 2023-05-08
US20230213519A1 (en) 2023-07-06
EP4121763A1 (en) 2023-01-25
BR112022017277A2 (pt) 2022-10-18
CN115769076A (zh) 2023-03-07
CA3171332A1 (en) 2021-09-23
WO2021185786A1 (en) 2021-09-23
AU2021237689A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
Tayyib et al. Saudi Arabian adult intensive care unit pressure ulcer incidence and risk factors: a prospective cohort study
Beidler et al. Multiplexed analysis of matrix metalloproteinases in leg ulcer tissue of patients with chronic venous insufficiency before and after compression therapy
Frantz et al. Baseline and serial brain natriuretic peptide level predicts 5-year overall survival in patients with pulmonary arterial hypertension: data from the REVEAL registry
Feldman A quantitative definition of severe psoriasis for use in clinical trials
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
MX2022011583A (es) Dpp3 en pacientes infectados con coronavirus.
Bugada et al. Effect of preoperative inflammatory status and comorbidities on pain resolution and persistent postsurgical pain after inguinal hernia repair
Belba et al. Epidemiology and outcome analysis of sepsis and organ dysfunction/failure after burns
MX2022002432A (es) Orientacion terapeutica y/o monitoreo terapeutico para el tratamiento de choques.
Ringen et al. Risks of a lifetime in construction. Part II: Chronic occupational diseases
Kapoor et al. Fibromyalgia in patients with rheumatoid arthritis: driven by depression or joint damage?
MX2023010635A (es) Método para el diagnóstico y el tratamiento de lesiones tisulares profundas a travez de mediciones de humedad subepidérmica.
Gupta et al. The prognostic significance of cardiac structure and function in atrial fibrillation: The ENGAGE AF–TIMI 48 Echocardiographic Substudy
BR112021026192A2 (pt) Marcador de diagnóstico para câncer pancreático
Sebbag et al. Investigation of Schirmer tear test-1 for measurement of tear production in cats in various environmental settings and with different test durations
Tay et al. Toe pressure in predicting diabetic foot ulcer healing: a systematic review and meta-analysis
MX2019000003A (es) Adrenomodulina para evaluar la congestión en un individuo con insuficiencia cardiaca aguda.
MX2021003164A (es) Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas.
Scharbatke et al. Association of improvement in pain with therapeutic response as determined by individual improvement criteria in patients with rheumatoid arthritis
Walsh et al. Treatment patterns with disease-modifying antirheumatic drugs in US Veterans with newly diagnosed rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
Williams et al. WIfi scoring: a reliable tool for risk stratification in the diabetic foot clinic
MX2022012600A (es) Ofatumumab para el tratamiento de ms mientras se mantiene la igg en el suero.
Kapur et al. Real world validation of VTE risk models in newly diagnosed multiple myeloma in a community setting
Hollenack et al. Pnd34 economic burden of probable Lennox-Gastaut syndrome, probable Dravet syndrome, and other refractory epilepsies for United States medicaid health plans
Wham et al. Prehospital ETCO2 is predictive of death in intubated and non-intubated patients